指南推荐的下腰痛干预措施的成本效益:一项系统综述
该系统综述纳入20项研究(17项试验内经济学评价和3项模型研究),评估指南推荐的非药物、非手术干预相比常规护理治疗非特异性下腰痛的成本效益。多数干预在20000英镑支付意愿阈值下具有成本效益;针对慢性下腰痛减少恐惧和压力或支持自我管理的干预,以及瑜伽、针灸、认知疗法和自我管理支持等临床医生实施的干预,可能节省成本。证据均来自高收入国家,中低收入国家证据有限。
要点
- 多数指南推荐的非药物、非手术干预在20000英镑/质量调整生命年阈值下具有成本效益。
- 针对慢性下腰痛减少恐惧和压力或支持自我管理的干预可能节省成本。
- 瑜伽、针灸、认知疗法和自我管理支持等临床医生实施的干预可能节省成本。
核心结论
- 包含教育、心理支持、针灸和运动的非药物、非手术干预相比常规护理治疗下腰痛似乎具有成本效益。
研究设计与样本
- 系统综述检索10个电子数据库从建库至2026年2月9日,纳入20项研究(17项试验内经济学评价和3项模型研究),发表于2005年至2026年。
- 10项研究聚焦慢性下腰痛(病程>3个月),8项纳入混合人群(急性、亚急性和慢性)。
- 所有研究均为非药物、非手术干预,包括单模式和 multimodal 干预(如运动加脊柱手法;饮食加身体活动)。
- 方法学质量分别采用CHEC清单(试验内经济学评价)或Philips清单(模型研究)评估。
- 该系统综述已在PROSPERO注册(CRD42024510270)。
主要发现
- 多数干预在20000英镑支付意愿阈值下具有成本效益。
- 针对慢性下腰痛减少恐惧和压力或支持自我管理的干预,以及瑜伽、针灸、认知疗法和自我管理支持等临床医生实施的干预,从医疗、社会和支付方角度可能节省成本,因为它们比常规护理(如包括建议和药物的首诊管理)更有效且成本更低。
- 所有证据均来自高收入国家,且文献异质性较大。
- 中低收入国家关于具有成本效益的治疗的证据仍然有限。
关键数值与推荐
- 主要结局为成本/质量调整生命年(QALY),转换为2024年英镑值并进行定性总结。
- 次要结局包括直接成本(总成本、干预成本、卫生服务使用、社区服务和自付费用)和间接成本(如工资损失、生产力损失、缺勤)。
临床怎么用
- 在常规护理中应改善这些有效治疗的可及性和实施,使更多人受益。
局限性
- 所有证据均来自高收入国家。
- 文献异质性较大。
- 中低收入国家证据有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Low back pain is the leading cause of disability worldwide. Although numerous treatment approaches are recommended by international clinical guidelines, there is still limited understanding of which interventions provide the best value for money. We aimed to critically appraise and summarise the evidence on the cost-effectiveness and costs of interventions endorsed in recent guidelines to manage low back pain (LBP), compared to usual care. METHODS AND FINDINGS: We searched 10 electronic databases (e.g., MEDLINE (OvidSP), EMBASE (OvidSP), PsycINFO (OvidSP)) from inception to 9th of February 2026 for cost-effectiveness studies of guideline-recommended treatments to manage non-specific LBP. The primary outcome was cost/quality-adjusted life year (QALY), which was converted to 2024 Great British Pound values, tabulated and summarised qualitatively. Secondary outcomes were direct costs (total, interventional, health service use, community services and out-of-pocket costs) and indirect costs (e.g., lost wages, lost productivity, absenteeism). We assessed methodological quality using the Consensus Health Economics Criteria (CHEC) checklist for within-trial economic evaluations or the Philips checklist for modelling studies. Our review included 20 studies (17 within-trial economic evaluations and three modelling studies), published between 2005 and 2026. Half (n = 10) focussed on chronic LBP (>3-month duration), and eight included mixed populations (i.e., acute, subacute and chronic). All studies were of non-pharmacological, non-surgical interventions, both single-modality and multimodal interventions (e.g., exercise plus spinal manipulation; diet plus physical activity). Most interventions are cost-effective at a willingness-to-pay threshold of £20,000. Moreover, interventions aiming to reduce fear and stress or support self-management in people with chronic LBP, as well as clinician-delivered interventions including yoga, acupuncture, cognitive therapy and self-management support are potentially cost-saving from the healthcare, societal and payer's perspectives, as they are both more effective and less costly than usual care (e.g., first contact management, including advice and medication). All of the evidence is derived from high-income countries, and from a considerable heterogenous body of literature. Evidence on cost-effective treatments in low- and middle-income countries remains limited. CONCLUSIONS: Non-pharmacological, non-surgical interventions that include education, psychological support, acupuncture and exercise seem to be cost-effective for managing LBP, compared to usual care. Improved access to and implementation of these effective treatments is urgently needed so more people can benefit from them in routine care. REGISTRATION: The review was registered on PROSPERO (https://www.crd.york.ac.uk; CRD42024510270).
引用
- Mathieson, Underwood, Ibrahim, et al. Cost-effectiveness of recommended interventions for managing low back pain: A systematic review. PLoS Med. 2026. PMID: 42945153. doi:10.1371/journal.pmed.1005273
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。